Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $60 Price Target
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $60 price target.
Login to comment